Xeris Biopharma Holdings Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
435
- Stock Symbol
-
XERS
- Investments
-
1
- Share Price
-
$16.65
- (As of Friday Closing)
Xeris Biopharma Holdings General Information
Description
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Contact Information
Website
www.xerispharma.comCorporate Office
- 1375 West Fulton Street
- Suite 1300
- Chicago, IL 60607
- United States
Corporate Office
- 1375 West Fulton Street
- Suite 1300
- Chicago, IL 60607
- United States
Xeris Biopharma Holdings Stock Performance
As of 13-Nov-2026, Xeris Biopharma Holdings’s stock price is $16.65. Its current market cap is $3.04B with 183M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.65 | $16.65 | $5.25 - $16.88 | $3.04B | 183M | 2.77M | -$0.03 |
Xeris Biopharma Holdings Financials Summary
As of 30-Sep-2026, Xeris Biopharma Holdings has a trailing 12-month revenue of $368M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,910,677 | 1,468,562 | 706,949 | 486,561 |
| Revenue | 368,259 | 291,845 | 203,070 | 163,914 |
| EBITDA | 28,834 | 37,589 | (19,315) | (28,486) |
| Net Income | (6,496) | 554 | (54,836) | (62,255) |
| Total Assets | 423,219 | 383,527 | 323,060 | 322,602 |
| Total Debt | 226,066 | 258,098 | 271,447 | 229,191 |
Xeris Biopharma Holdings Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Xeris Biopharma Holdings Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Xeris Biopharma Holdings Comparisons
Industry
Financing
Details
Xeris Biopharma Holdings Competitors (37)
One of Xeris Biopharma Holdings’s 37 competitors is Savara, a Formerly VC-backed company based in Yardley, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Savara | Formerly VC-backed | Yardley, PA | ||||
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| ABIONYX Pharma | Formerly VC-backed | Balma, France | ||||
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Xeris Biopharma Holdings Patents
Xeris Biopharma Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260248724-A1 | Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof | Pending | 25-Feb-2025 | ||
| WO-2026183248-A1 | Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof | Pending | 25-Feb-2025 | ||
| AU-2023364195-A1 | Stable levothyroxine compositions in aprotic polar solvents | Pending | 19-Oct-2022 | ||
| EP-4604922-A1 | Stable levothyroxine compositions in aprotic polar solvents | Pending | 19-Oct-2022 | ||
| US-12514837-B2 | Stable levothyroxine compositions in aprotic polar solvents | Active | 19-Oct-2022 | A61K31/198 |
Xeris Biopharma Holdings Signals
Xeris Biopharma Holdings Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Xeris Biopharma Holdings Acquisitions (1)
Xeris Biopharma Holdings’s most recent deal was a Merger/Acquisition with Strongbridge Biopharma for . The deal was made on 05-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Strongbridge Biopharma | 05-Oct-2021 | Merger/Acquisition | Pharmaceuticals |
Xeris Biopharma Holdings ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.26 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Xeris Biopharma Holdings FAQs
-
When was Xeris Biopharma Holdings founded?
Xeris Biopharma Holdings was founded in 2005.
-
Where is Xeris Biopharma Holdings headquartered?
Xeris Biopharma Holdings is headquartered in Chicago, IL.
-
What is the size of Xeris Biopharma Holdings?
Xeris Biopharma Holdings has 435 total employees.
-
What industry is Xeris Biopharma Holdings in?
Xeris Biopharma Holdings’s primary industry is Pharmaceuticals.
-
Is Xeris Biopharma Holdings a private or public company?
Xeris Biopharma Holdings is a Public company.
-
What is Xeris Biopharma Holdings’s stock symbol?
The ticker symbol for Xeris Biopharma Holdings is XERS.
-
What is the current stock price of Xeris Biopharma Holdings?
As of 13-Nov-2026 the stock price of Xeris Biopharma Holdings is $16.65.
-
What is the current market cap of Xeris Biopharma Holdings?
The current market capitalization of Xeris Biopharma Holdings is $3.04B.
-
What is Xeris Biopharma Holdings’s current revenue?
The trailing twelve month revenue for Xeris Biopharma Holdings is $368M.
-
Who are Xeris Biopharma Holdings’s competitors?
Savara, Blueprint Medicines, Rhythm Pharmaceuticals, ABIONYX Pharma, and Crinetics Pharmaceuticals are some of the 37 competitors of Xeris Biopharma Holdings.
-
What is Xeris Biopharma Holdings’s annual earnings per share (EPS)?
Xeris Biopharma Holdings’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process